Form 4 for LH Labcorp
Accepted 2022-11-03 00:00:00 ET · period of report 2022-11-01 · accession 0001127602-22-024923 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-11-03 | 2022-11-01 | LH | EISENBERG GLENN A | CFO, EVP | F - Tax | $222.56 | -5,348 | 33.8K | -14% | -$1.19M |
| D | 2022-11-03 | 2022-11-01 | LH | EISENBERG GLENN A | CFO, EVP | M - OptEx | — | +12.0K | 39.2K | +44% | — |
| DM | 2022-11-03 | 2022-11-01 | LH | EISENBERG GLENN A | CFO, EVP | A - Grant | $0.00 | +18.3K | 9,170 | New | $0 |
| D | 2022-11-03 | 2022-11-01 | LH | EISENBERG GLENN A | CFO, EVP | M - OptEx | $0.00 | -12.0K | 13.8K | -46% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-01 | F | D | 5,348 | $222.56 | 33,842 | D | — | — | |
| 2 | Common | Common Stock | 2022-11-01 | M | A | 12,032 | — | 39,190 | D | — | — | (F1) Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. |
| 3 | Derivative | Restricted Stock Unit | 2022-11-01 | A | A | 9,170 | $0.00 | 25,876 | D | — · — to — | 9,170 Common Stock | (F1) Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. (F6) The Restricted Stock Units vest in full on April 15, 2024. |
| 4 | Derivative | Performance Share Unit | 2022-11-01 | A | A | 9,170 | $0.00 | 9,170 | D | — · — to 2024-05-10 | 9,170 Common Stock | (F3) Performance Share Unit granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. (F4) Each Performance Share Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. (F5) The Performance Share Units vest in full upon the filing of the Company's Quarterly Report on Form 10-Q for the first quarter of 2024, subject to both continued service and a performance condition related to the Issuer's contemplated spin-off transaction. |
| 5 | Derivative | Restricted Stock Unit | 2022-11-01 | M | D | 12,032 | $0.00 | 13,844 | D | — · — to — | 12,032 Common Stock | (F8) This number reflects the aggregate number of Restricted Stock Units held by the reporting person. (F1) Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. (F7) The Restricted Stock Units that have vested were part of a grant that vested in three installments as follows: 30% of the Restricted Stock Units vested on November 1, 2020; 30% of the Restricted Stock Units vested on November 1, 2021; and 40% of the Restricted Stock Units vested on November 1, 2022, with the third installment subject to a relative total shareholder return ("TSR") modifier that could have adjusted the third installment of the Restricted Stock Units upward or downward 25% based on our three-year cumulative relative TSR but ultimately did not result in an adjustment. |